ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2020
The Health and Economic Burdens of Lymphatic Filariasis Prior to Mass Drug Administration Programs.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Haematological and biochemical profiling combined with HRAMS-based metabolomics reveals the potential biomarkers ofRSC advances · 2026Article
- Integrated surveillance for lymphatic filariasis and other infectious diseases with a nationwide non-communicable disease STEPwise survey in the small Pacific Island Nation of Niue, 2025.Scientific reports · 2026Article
- When is elimination of an infectious disease cost-effective? An analytical framework to guide elimination priorities.Cost effectiveness and resource allocation : C/E · 2026Article
- Post elimination of lymphatic filariasis: a situation analysis of brugian filariasis and vector potentialities within the filarial transmission belt in Sri Lanka.Parasites & vectors · 2026Article
- Structural insights of WBmDapE and deciphering of potent anti-filarial inhibitors: a state-of-art computational approach.Molecular diversity · 2026Article
- Global Lymphatic Filariasis Post-Validation Surveillance Activities in 2025: A Scoping Review.Tropical medicine and infectious disease · 2026Review
- An Unusual Presentation of Human Parotid Filariasis.Tropical medicine and infectious disease · 2025Article
- Fexinidazole and Corallopyronin A target Wolbachia-infected sheath cells present in filarial nematodes.PLoS pathogens · 2025Article
- Current perspectives in the epidemiology and control of lymphatic filariasis.Clinical microbiology reviews · 2025Review
- Fexinidazole and Corallopyronin A targetbioRxiv : the preprint server for biology · 2025Article
- Managing Lymphedema Induced by Lymphatic Filariasis: Implementing and Improving Care at the Individual and Programmatic Levels.The American journal of tropical medicine and hygiene · 2024Article
- The effects of selected neglected tropical diseases on economic performance at the macrolevel in Africa.BMC infectious diseases · 2024Article
- Reducing the Antigen Prevalence Target Threshold for Stopping and Restarting Mass Drug Administration for Lymphatic Filariasis Elimination: A Model-Based Cost-effectiveness Simulation in Tanzania, India and Haiti.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Zambia: A Narrative Review of Success and Challenges in Lymphatic Filariasis Elimination.Tropical medicine and infectious disease · 2024Review
- Lymphedema after saphenous harvesting for coronary artery bypass surgery: case report and literature review.BMC cardiovascular disorders · 2024Review
- Implementation and Outcomes of a Pilot Collaborative Surgical Hydrocele Training in Côte d'Ivoire.The American journal of tropical medicine and hygiene · 2024Article
- Economic Burden of Mosquito-Borne Diseases in Low- and Middle-Income Countries: Protocol for a Systematic Review.JMIR research protocols · 2023Article
- Detection of Wuchereria bancrofti in human blood samples and mosquitoes in Matayos, Busia County-Kenya.Scientific reports · 2023Article
- Evaluating the availability and quality of services for lymphatic filariasis morbidity in Ghana.PLoS neglected tropical diseases · 2023Article
- A nationwide epidemiological and geodemographic analysis of lymphatic filariasis in Ecuador: a neglected and often forgotten disease in Ecuador.Frontiers in public health · 2023Article
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
Abstract
backgroundThe Global Programme to Eliminate Lymphatic Filariasis (GPELF) was launched in 2000 with the goal of eliminating lymphatic filariasis (LF) as a public health problem by 2020. Despite considerable progress, the current prevalence is around 60% of the 2000 figure, with the deadline looming a year away. Consequently, there is a continued need for investment in both the mass drug administration (MDA) and morbidity management programs, and this paper aims to demonstrate that need by estimating the health and economic burdens of LF prior to MDA programs starting in GPELF areas.
methodsA previously developed model was used to estimate the numbers of individuals infected and individuals with symptomatic disease, along with the attributable number of disability-adjusted life years (DALYs). The economic burden was calculated by quantifying the costs incurred by the health-care system in managing clinical cases, the patients' out-of-pocket costs, and their productivity costs.
resultsPrior to the MDA program, approximately 129 million people were infected with LF, of which 43 million had clinical disease, corresponding to a DALY burden of 5.25 million. The average annual economic burden per chronic case was US $115, the majority of which resulted from productivity costs. The total economic burden of LF was estimated at US $5.8 billion annually.
conclusionsThese results demonstrate the magnitude of the LF burden and highlight the continued need to support the GPELF. Patients with clinical disease bore the majority of the economic burden, but will not benefit much from the current MDA program, which is aimed at reducing transmission. This assessment further highlights the need to scale up morbidity management programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.